Physician profile
Keith Lawhorn
NPI 1083614218
$1,639,136.73
in general payments reported to CMS, 2019-2025
11 companies · $258K in 2025
The $258K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $143K · 2021: $292K · 2022: $305K · 2023: $301K · 2024: $248K · 2025: $258K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $729K · Consulting Fee: $74K · Travel and Lodging: $2,958 · Food and Beverage: $1,639 · Education: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $728,739.69 |
| Consulting Fee | $73,750.00 |
| Travel and Lodging | $2,957.56 |
| Food and Beverage | $1,638.63 |
| Education | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,637,658.87 | 2019-2025 | Juggerstitch, Juggerknotless Soft Anchor, Toggleloc |
| Aesculap Biologics, LLC | $731.42 | 2021 | |
| Medacta USA, INC. | $232.84 | 2020-2021 | |
| Vericel Corporation | $203.68 | 2020-2025 | Maci |
| Supreme Orthopedic Systems, LLC | $130.65 | 2024 | |
| Smith+Nephew, INC. | $55.77 | 2021-2022 | |
| Depuy Synthes Sales INC. | $52.96 | 2023 | Monovisc, Orthovisc, Peak |
| Bioventus LLC | $26.50 | 2019 | |
| Stryker Corporation | $16.66 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $15.52 | 2021 | |
| Arteriocyte Medical Systems, INC. | $11.86 | 2023 | Magellan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lawhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.